Home         Forums  

Go Back   Marrowforums > Treatments > Clinical Trials
Register FAQ Search Today's Posts Mark Forums Read

Clinical Trials Considering or participating in research studies

Reply
 
Thread Tools Search this Thread
  #1  
Old Wed Apr 17, 2013, 11:56 PM
Heather8773 Heather8773 is offline
Member
 
Join Date: Jan 2013
Location: Houston, TX
Posts: 239
Anyone heard about hemaxellerate in clinical trials AA?

Anyone heard of this or any thoughts? New treatment about to be in clinical trials for AA.
Sorry I wasn't sure how to post the link..


Regen BioPharma Files Investigational New Drug (IND) Application With FDA on HemaXellerate I(TM) Stem Cell Drug for
SAN DIEGO, CA&(Marketwire & Feb 5, 2013) & Regen BioPharma a wholly-owned subsidiary of Bio-Matrix Scientific Group Inc. ( PINKSHEETS : BMSN ), announced today filing of an Investigational New Drug (IND) application with the FDA to initiate clinical trials assessing the company&s HemaXellerate I stem cell drug in patients with drug-refractory aplastic anemia.

HemaXellerate I is a patient-specific composition of cells that have previously been demonstrated to repair damaged bone marrow and stimulate production of blood cells based on previous animal studies.The company, together with an internationally-renowned group of stem cell researchers, recently published the scientific basis for the HemaXellerate I product which may be found at http://www.translational-medicine.co...876-10-231.pdf.

&Currently patients with aplastic anemia who are resistant to drugs and ineligible for bone marrow transplant have no therapeutic options.We are fortunate to be in the position to have developed a novel approach to potentially treat this terrible condition,& said David Koos, CEO of Bio-Matrix.&To our knowledge the HemaXellerate I product is the only therapy that has potential to simultaneously block the underlying cause of aplastic anemia while at the same time rebuilding the bone marrow tissue that has been damaged by the disease.&

If the clinical trial is successful, the company plans to expand use of HemaXellerate I to other conditions associated with bone marrow dysfunction, with the overall goal of entering the hematopoietic growth factor market.This market is substantial in size and currently includes drugs such as Neupogen, Neulasta, Leukine and Revolade.

&Current drug-based approaches for healing bone marrow damage involve &flooding& the body with growth factors, which is extremely expensive and causes unintended consequences because of lack of selectivity,& said Dr. Vladimir Bogin, CEO of Chromos Pharma (a contract research organization), which collaborated with Regen on filing the IND and member of the Company&s Scientific Advisory Board. &Based on our data HemaXellerate I possesses the advantage delivering an optimized cellular mixture that produces the needed growth factors at the specific location in the bone marrow niche.&

The planned clinical trial anticipates recruiting 10 patients who have failed standard of care, which will be treated with HemaXellerate I and followed for safety parameters and signals of efficacy.Therapeutic effects will be quantified based on immunological measurements, as well as improvement in blood counts.Patients in the trial will be assessed for one year, however, because the trial is unblinded, data will be available as the study progresses.

About Bio-Matrix Scientific Group Inc. and Regen BioPharma, Inc.:

Bio-Matrix Scientific Group, Inc. ( PINKSHEETS : BMSN ) is a biotechnology company developing regenerative medicine therapies. The Company is focused on human therapies that address unmet medical needs. Specifically, Bio-Matrix Scientific Group Inc. is looking to increase the quality of life through therapies involving stem cell treatments. These treatments are focused in areas relating to cardiovascular, hematology, oncology and other indications.

Regen BioPharma, Inc., a subsidiary of Bio-Matrix Scientific Group, Inc. ( PINKSHEETS : BMSN ), is a biotechnology company focused on identifying undervalued regenerative medicine patents in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. To follow our development, visit us at www.regenbiopharma.com.

Disclaimer

Here is the original post:
Regen BioPharma Files Investigational New Drug (IND) Application With FDA on HemaXellerate I(TM) Stem Cell Drug for &
__________________
Heather, wife of Ronald age 31; dx PNH 2012; Dx VSAA 2013; previously on eculizumab(Solaris) hATG 2/20/13 cyclosporine 400 mg daily. 37 units RBC and 15 units of platelets.
Now -pentam,vorconizole,valtrex, valcyte, actigall, multivitamin, Pepcid , prograf, magnesium.
10/10 MUD 10/10/13
Reply With Quote
Reply


Thread Tools Search this Thread
Search this Thread:

Advanced Search

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

vB code is On
Smilies are On
[IMG] code is On
HTML code is Off
Forum Jump

Similar Threads
Thread Thread Starter Forum Replies Last Post
Clinical Trials at NIH - Question about lodging Al's Wife Clinical Trials 6 Wed Aug 10, 2011 09:28 PM
Clinical Trials Vince R Clinical Trials 2 Tue Feb 16, 2010 01:18 PM
Has anyone heard about this Blood Tonic? And what about AA prognosis? paulaespada AA 5 Fri Oct 17, 2008 03:46 AM
A special forum for reports from clinical trials Birgitta-A Site Comments 2 Sun Oct 14, 2007 02:43 PM


All times are GMT -4. The time now is 10:54 PM.


Powered by vBulletin® Version 3.6.7
Copyright ©2000 - 2017, Jelsoft Enterprises Ltd.
Forum sites may contain non-authoritative and unverified information.
Medical decisions should be made in consultation with qualified medical professionals.
Site contents exclusive of member posts Copyright 2006-2016 Marrowforums.org